Tanashyan, M, Morozova, S, Raskurazhev, A et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023 · DOI
Researchers tested whether a drug called CCSA (a compound containing succinate acid) could help people with post-COVID fatigue and brain fog. They used advanced brain imaging scans to measure changes in brain activity before and after treatment. The CCSA group showed greater improvement in fatigue symptoms and thinking skills compared to the placebo group.
Post-COVID fatigue shares phenotypic overlap with ME/CFS, and this study provides objective neuroimaging evidence linking symptom improvement to measurable changes in brain function. Understanding neuroprotective mechanisms in post-COVID populations may inform therapeutic approaches applicable to ME/CFS, where cognitive dysfunction and fatigue are core features.
This study does not prove CCSA is effective for ME/CFS or primary post-viral fatigue broadly—findings are specific to post-COVID asthenic syndrome in this sample. Small sample size (n=15 per group) limits generalizability. The study demonstrates correlation between neuroimaging changes and clinical improvement but does not establish whether brain imaging changes are mechanistically responsible for symptom relief or merely associated with it.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →